Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a strong-buy rating in a report issued on Thursday morning,Zacks.com reports.

Several other research firms have also recently issued reports on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Supernus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Up 1.9%

SUPN opened at $47.64 on Thursday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of -24.81, a PEG ratio of 0.76 and a beta of 0.56. Supernus Pharmaceuticals has a 12-month low of $40.26 and a 12-month high of $59.68. The stock’s 50-day moving average price is $46.17 and its 200 day moving average price is $48.93.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $434,871,000. Deutsche Bank AG purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $2,964,000. Rice Hall James & Associates LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $22,800,000. Global Retirement Partners LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $64,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $17,553,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.